Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 369-379, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-775618
ABSTRACT
In recent years, research on immunotherapy has made great progress. Currently, immunotherapy has made significant breakthrough, especially programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors (e.g, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab and Avelumab, etc.) have brought clinical benefits to patients with various pathological types of lung cancer, including squamous cell carcinoma, adenocarcinoma and small cell lung cancer. In this paper, the application value and current status of PD-1/PD-L1 checkpoint inhibitors in lung cancer were comprehensively analyzed by reviewing and interpreting representative clinical studies. Based on the results of various large-scale clinical trials results, the indications of immunotherapy in lung cancer have been continuously broadened, and the details of immunotherapy have also been constantly optimized. However, immunotherapy still faces many challenges, such as the selection of immune combination strategies, the exploration of biomarkers, the management of adverse events, the feasibility of application of driver gene mutation population and so on. In this article, we made a systematic review about the latest progress of PD-1/PD-L1 checkpoint inhibitors in lung cancer, in order to provide cutting-edge reference for the clinical workers.
.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Usos Terapêuticos
/
Tratamento Farmacológico
/
Alergia e Imunologia
/
Antígeno B7-H1
/
Receptor de Morte Celular Programada 1
/
Antineoplásicos Imunológicos
/
Genética
/
Imunoterapia
/
Neoplasias Pulmonares
/
Metabolismo
Limite:
Animais
/
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS